<DOC>
	<DOCNO>NCT02416388</DOCNO>
	<brief_summary>This open label , multicenter phase III study multiple randomization phase differents stage AML treatment ( induction , consolidation HSCT applicable ) design improve OS younger ( 18 60 year-old ) patient , AML risk-adapted patient strategy . Within intermediate risk AML group , optimal GvHD prophylaxis follow allogeneic SCT first CR , either myeloablative ( MAC ) reduce intensity ( RIC ) conditioning , also evaluate . With adaptative design , clinical trial test 3 molecule new AML agent interest come near future .</brief_summary>
	<brief_title>Study Improve OS 18 60 Year-old Patients , Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens , High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens , Standard Versus MMF Prophylaxis GvHD Allografted Patients First CR</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion Criteria ( diagnosis ) : 1 . Age ≥ 18 year &lt; 61 year 2 . With newly diagnose de novo secondary type AML ( post myelodysplastic syndrome MDS therapyrelated AML ) 3 . No prior treatment AML , exception hydroxyurea 4 . ECOG performance status ≤ 3 5 . No contraindication anthracyclines : decompensated uncontrolled heart failure , recent myocardial infarction , current sign cardiac impairment , uncontrolled arrhythmia , LVEF ( leave ventricular ejection fraction ) &lt; 50 % 6 . Total bilirubin ≤ 2 x upper limit normal ( UNL ) , ASAT ( SGOT ) ALAT ( SGPT ) ≤ 2.5 X UNL , creatinine &lt; 150 µmol/l , unless AMLrelated range value 7 . Women childbearing potential use appropriate method contraception 8 . Health insurance coverage 9 . Signed informed consent Exclusion criterion ( diagnosis ) : 1 . Patients acute promyelocytic leukemia ( APL ) , confirm either ( 15 ; 17 ) presence PMLRARA fusion transcript 2 . Patients core bind factor ( CBF ) AML , confirm either ( 8 ; 21 ) , ( 16,16 ) inv ( 16 ) , fusion transcript result cytogenetic abnormality ( RUNX1RUNX1T1 , CBFBMYH11 ) . 3 . Patients secondary AML arise myeloproliferative disorder previously know accord 2008 WHO classification 4 . Patients Ph1+ AML previous Ph1+ disorder ( chronic myelogenous leukemia ) 5 . Severe pshyciatric organic disorder , suppose independent AML , would contraindicate treatment , include allogeneic HSCT 6 . No psychological , familial , social , geographic reason would compromise clinical follow 7 . History uncontrolled cancer last 2 year , exception basal cell carcinoma carcinoma situ cervix 8 . Uncontrolled severe infection 9 . Patients positive serology HIV1 2 , HTLV 1 2 , active hepatitis virus B C infection 10 . Pregnant lactate woman 11 . Legal incapacity ( patient tutorship , curatorship judicial protection ) For randomization R3 : Inclusion criterion 1 . Patients enrol BIG1 trial diagnosis 2 . Patients achieve first CR induction salvage therapy 3 . Patients belong intermediate AML risk group define protocol BIG1 4 . Signed informed consent R3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>